M.B.A., B.A, Founder and Chief Strategy Officer, CardioDx
David founded CardioDx in 2004, and served as the President and Chief Executive Officer of the company until 2016. David drove the successful commercialization of the Corus CAD blood test with over 250,000 patients having received and benefited from the Corus CAD test. Prior to launching CardioDx, David was a Venture Partner at Texas Pacific Group Ventures and was also the interim Chief Executive Officer and Director of CareDx (formerly XDx, Inc.). Previously, he was the Founder, President, and Chief Executive Officer of iScribe, a healthcare technology company acquired by AdvancePCS (now Caremark). Prior to iScribe, David was President of Oncology Therapeutics Network (OTN), which was acquired by Bristol-Myers Squibb in 1996. Prior to OTN, he was with Cole Gilburne Fund, an early-stage, technology-focused venture capital firm. David continues to serve as a Director on both public and private Boards.
Presentation Title and Company Description
Clinical Dx Showcase: Learnings From Precision Diagnostics in Cardiovascular Care
CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, is developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, CardioDx is committed to expanding patient access and improving healthcare quality and efficiency through the commercialization of genomic technologies.